Does targeting of the antivascular drug combretastatin to irradiated tumors result in tumor growth delay?
These findings indicate that preferential targeting of antivascular drugs to irradiated tumors results in significant tumor growth delay.
Moderate CKD is a significant independent predictor of fracture occurrence.